Tag:

Teva Pharmaceutical

Latest Headlines

Latest Headlines

Teva's SCOTUS appeal is here. But how much can the outcome really affect Copaxone's market share?

Teva pushed hard for a Supreme Court appeal after a federal court last summer upturned its patents on cash cow Copaxone. Today, SCOTUS is due to hear oral arguments for the case. But when it comes to Teva's market share, other factors may have just as big an impact as the court's decision.

Teva closing up women's health unit Theramex, thanks to lousy Zoely sales

We've seen what happens when a big drug goes generic. Plants close, sales reps lose their jobs. As the impending shutdown of a Teva Pharmaceutical Industries unit shows, the same is true for an on-patent drug flop.

UPDATED: In management reorg, Teva taps Actavis alum to helm new global generics unit

Teva Pharmaceutical Industries CEO Erez Vigodman has been a busy man. So busy, in fact, it seems the company's press releases barely keep up with him. Today's announcement: Vigodman has overhauled Teva's management structure, winnowing out 6 executive jobs and creating two worldwide divisions. And he recruited a pharma-industry vet to take the helm of one of them.

Teva recalls drugs made by India's Emcure over lab testing issues

The company is recalling about 40,000 bottles of drugs manufactured for it by Emcure Pharmaceuticals in India for deviations in lab testing, an issue the FDA has frequently uncovered at Indian plants.

Facing a PR crisis? Teva France's chief has some hard-won advice

Last June, reports surfaced that a patient had died, allegedly because of Teva's diuretic, Furosémide. In an interview with EuropeanCEO, Teva France CEO Erick Roche outlined how he helped the company survive the PR onslaught.

Teva hit with $27.6M settlement in clozapine kickback case

Israel's Teva Pharmaceutical has agreed to pay $27.6 million to settle allegations that it illegally paid a Chicago doctor to prescribe the generic antipsychotic drug clozapine to Medicare and Medicaid patients.

Can Teva persuade payers that pricey long-acting Copaxone beats cheap generics?

Teva is on a mission. The goal: switch as many multiple sclerosis patients as possible over to the new version of Copaxone before the current product loses patent protection in May. So far, Teva has reached 85,000 of them; to do so, Bloomberg reports, the company has started emailing patients registered with its 24-hour patient-support hotline.

Feds target Teva in probe of Copaxone, Azilect marketing

After investigating Teva Pharmaceutical Industries for potential bribery overseas in 2012, U.S. prosecutors have turned to Teva's marketing, eyeing two branded medications, its top-selling multiple sclerosis drug Copaxone and its Parkinson's disease treatment Azilect.

MDxHealth teams up with Teva to distribute its prostate, brain cancer tests

Belgium's MDxHealth has partnered with generics maker Teva Pharmaceuticals to commercialize its ConfirmMDx for prostate cancer and PredictMDx for glioblastoma tests in Israel.

UPDATED: Corks are a-popping at Teva with FDA nod for its new Copaxone formula

Brace yourselves for the Teva Pharmaceutical Industries marketing blitz. The company won FDA approval Tuesday evening for its new, three-times-a-week Copaxone, and Teva needs to convert as many patients as possible to the new version before the original goes off patent in May.